1 / 12

Radioimmunotherapy

Radioimmunotherapy. Allison Spencer July 27, 2006. Radioimmunotherapy. Uses the body’s immune system to deliver toxic radiation to cancerous cells Special combination of factors: Tumor antigen targeting Monoclonal antibodies Radionuclides Localized treatment. Bio 101: Antigens.

eyad
Télécharger la présentation

Radioimmunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Radioimmunotherapy Allison Spencer July 27, 2006

  2. Radioimmunotherapy • Uses the body’s immune system to deliver toxic radiation to cancerous cells • Special combination of factors: • Tumor antigen targeting • Monoclonal antibodies • Radionuclides • Localized treatment

  3. Bio 101: Antigens • Molecules that stimulate an immune response • Proteins or polysaccharides on cell surfaces • Many different types • Tumor Antigens • Tumor Associated • Tumor Specific

  4. Bio 101: Antibodies • Large, Y shaped proteins • Identify and neutralize antigens • Induce apoptosis • Cell cycle redistribution • Multiple antibodies for every antigen

  5. Monoclonal Antibodies • Highly specific • Clones of single cell • Fuse B cell and tumor cell • Screen for antibody production

  6. Radioimmunotherapy • Adds a radioactive molecule to a monoclonal antibody (MoAb) Yttrium 90 labeled MoAb

  7. Non-Hodgkin’s Lymphoma • 58,870 cases will be diagnosed in 2006 • 5th leading cause of cancer death • Traditionally treated with: • Chemotherapy • External beam therapy • Immunotherapy

  8. RIT and Non-Hodgkin’s Lymphoma • Specific antigen targeted: CD20 • Tumor associated • Does not shed or internalize • Isotopes used: • Yttrium-90: half life 64 hours, beta emitter • Iodine-131: half life 8 days, alpha and gamma • Vary in conjugation

  9. Process of Attack Cancerous B Cell 90Y

  10. Advantages of RIT • Precision of treatment • Less damage to healthy tissue • Irradiation of nearby, unbound cells • Patient comfort • 1 hour intravenous procedure • Y-90 outpatient administration Unbound cells receive toxic radiation

  11. RIT Success in NHL • With traditional treatments: • Low grade kills ~95% of patients in first 5 years • Aggressive kills ~50% of patients in first 5 years • Yttrium-90 labeled Zevalin: • 80% overall response rate with Y-90 Zevalin • 34% complete response • 32% still in remission 3-4 years later

  12. Radioimmunotherapy Allison Spencer

More Related